LUMO Share Price Performance
US$0
0.00 (0.00%)
Price US$0
Share Pricen/a
Lumos Pharma, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
LUMO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Lumos Pharma, Inc. Key Details
Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
- -4.04
- 100.00%
- -1,583.49%
- 0%
About LUMO
- Founded
- n/a
- Employees
- 30
- CEO
- WebsiteView website
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
